1. Cyhoeddwyd

   Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

   Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Rhag 2012, Yn: Value in Health. 15, 8, t. 1162-1171

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

   Hughes, D. & Hughes, D. A., 1 Tach 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   Welsh Health Economics Network (WHEN): Scoping Report.

   Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

4. Cyhoeddwyd

   Understanding medication compliance and persistence from an economics perspective

   Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

   Hughes, D., Linley, W. G. & Hughes, D. A., 1 Ebr 2013, Yn: Pharmacoeconomics. 31, 4, t. 345-355

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Biosimilars: Evidential standards for health technology assessment.

   Hughes, D. & Hughes, D. A., 1 Ion 2009.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

8. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

9. Cyhoeddwyd

   Pharmacogenetic tests: the need for a level playing field

   Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group

    Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Lal, L., Salas, M., Hughes, D. A., Ratzki-Leewing, A. & Grubisic, M., 1 Gorff 2013, Yn: Value in Health. 16, 5, t. 863-871

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid